ResMed Inc.
ResMed Announces Strong Q2 2026 Financial Results and Dividend Declaration
Summary
ResMed Inc. announced its financial results for the quarter ended December 31, 2025, reporting an 11% increase in revenue to $1.4 billion. The company saw a 320 basis points increase in gross margin to 61.8%, and non-GAAP diluted earnings per share (EPS) reached $2.81, reflecting strong sales growth and gross margin improvement. Additionally, the board declared a quarterly cash dividend of $0.60 per share, payable on March 19, 2026.
Profitelligence Alerts
Get alerts for RMD
Be first to know when ResMed Inc. files with the SEC.
Filing Categories
Advertisement
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Official SEC Documents
Advertisement